The content on this site is intended for healthcare professionals only
Prof Monica Morrow speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about managing patients with HER2-positive breast cancer.
She speaks about the benefits of neo-adjuvant therapies for these patients, giving her practical advice for management strategies and discussing recent relevant research.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Breast conserving surgery and IORT can manage locally recurrent breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The role of lymph nodes in stage 3 lung cancer
The role of multidisciplinary tumour board in managing stage 3 lung cancer
COMMENT: Women Who Conquer Cancer
